UPDATE - UBS Initiates Coverage on Accretive Health (AH) with a Buy; The Right Offerings at the Right Time
Tweet
Share
E-mailGet Alerts AH Hot Sheet
Price: $8.02 --0%
Rating Summary:
2 Buy, 6 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 15 | New: 40
Rating Summary:
2 Buy, 6 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 15 | New: 40
Join SI Premium – FREE
UPDATE - UBS initiates coverage on Accretive Health (NYSE: AH) with a Buy. PT $29.00
UBS analyst says, "AH’s end-to-end revenue cycle management (RCM) combines technology, people and process to deliver large and sustainable margin improvements for hospitals. We believe AH’s RCM value proposition is the most compelling versus competitors and should help drive its market penetration to ~5% by 2014 (currently ~2%)."
"In our view, Accretive’s ‘quality and total cost of care’ offering and ‘physician advisory services’ appear to be ramping ahead of expectations. We believe these two recently introduced offerings may offer upside to numbers."
To see more ratings changes on AH, Click Here
UBS analyst says, "AH’s end-to-end revenue cycle management (RCM) combines technology, people and process to deliver large and sustainable margin improvements for hospitals. We believe AH’s RCM value proposition is the most compelling versus competitors and should help drive its market penetration to ~5% by 2014 (currently ~2%)."
"In our view, Accretive’s ‘quality and total cost of care’ offering and ‘physician advisory services’ appear to be ramping ahead of expectations. We believe these two recently introduced offerings may offer upside to numbers."
To see more ratings changes on AH, Click Here
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UBS Starts Urban Company (URBANCO:IN) at Buy
- BMO Capital Starts D-Wave Quantum Inc. (QBTS) at Outperform
- BMO Capital Starts Broadcom Limited (AVGO) at Outperform
Create E-mail Alert Related Categories
New CoverageRelated Entities
UBSSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
